A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Model scores of the 29,894 trials active now.

Model score 18% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (257 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-03-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: greaterstagefunctionstabledl
  Phrases that lowered it: study drugopenvisitlabelcondom
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.4% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 100% (raises risk) · Drug's FDA history
• Phase: 1/2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 57 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 135 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 5 (lowers risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors NCT02501096 · started 2015 · scored riskier than 71% of active trials completed
• Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma NCT01605162 · started 2012 · scored riskier than 85% of active trials terminated
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors NCT01618136 · started 2012 · scored riskier than 90% of active trials completed
• A Study of AGEN2034 in Advanced Tumors and Cervical Cancer NCT03104699 · started 2017 · scored riskier than 67% of active trials completed
• A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) NCT03495882 · started 2017 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.